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Clinical Implications of Immunohistochemically Demonstrated 
Lymph Node Micrometastasis in Resectable Pancreatic Cancer 
The purpose of this study was to determine the clinical significance of nodal 
micrometastasis detected by immunohistochemistry in patients that had undergone 
curative surgery for pancreatic cancer. Between 2005 and 2006, a total of 208 lymph 
nodes from 48 consecutive patients with pancreatic cancer that had undergone curative 
resection were immunostained with monoclonal antibody against pan-ck and CK-19. 
Micrometastasis was defined as metastasis missed by a routine H&E examination but 
detected during an immunohistochemical evaluation. Relations between 
immunohistochemical results and clinical and pathologic features and patient survival were 
examined. Nodal micrometastases were detected in 5 (29.4%) patients of 17 pN0 patients. 
Nodal micrometastasis was found to be related to tumor relapse (P = 0.043). Twelve 
patients without overt nodal metastasis and micrometastasis had better prognosis than  
5 patients with only nodal micrometastasis (median survival; 35.9 vs 8.6 months,  
P < 0.001). The Cox proportional hazard model identified nodal micrometastasis as 
significant prognostic factors. Although the number of patients with micrometastasis was 
so small and further study would be needed, our study suggests that the lymph node 
micrometastasis could be the predictor of worse survival and might indicate aggressive 
tumor biology among patients undergoing curative resection for pancreas cancer.  
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION 
Ductal adenocarcinoma of the pancreas is a highly aggressive 
malignancy with a remarkably poor prognosis, and unfortunate-
ly, even for patients with apparently localized surgically resect-
able disease, long-term survival after curative resection remains 
poor. In fact, majority of patients with pancreatic cancer suffer 
from postoperative local recurrence or distant metastasis de-
spite histologically confirmed curative resection and tumor free 
lymph nodes. These recurrences are thought to arise from occult 
tumor cell dissemination or micrometastatic disease that can-
not be detected using current staging procedures (1-3). Accord-
ingly, more sensitive techniques, such as immunohistochemis-
try and molecular biology assays, to detect minimal residual dis-
ease of pancreatic cancer with the potential for metastasis have 
been introduced. Immunohistochemical assays were the earli-
est to be developed, and these are more frequently used than 
other alternatives in several cancers including those of the breast 
(4, 5), lung (6, 7), stomach (8, 9), and colon (10, 11). The majori-
ty of studies have used antibodies against a broad spectrum of 
cytokeratins (CK) (4-11). However, little is known about the clin-
ical significance of nodal micrometastasis in pancreatic cancer 
(12-15). Accordingly, we conducted this study to investigate the 
clinical significance of nodal micrometastasis detected by im-
munohistochemical staining with antibodies against cytokera-
tin (pan-CK and CK-19) in pancreatic cancer patients that had 
undergone curative surgery. 
MATERIALS AND METHODS 
Patients 
Forty-eight patients who underwent macroscopically curative 
resection (12 cases of pancreatoduodenectomy and 36 cases of 
pylorus preserving pancreatoduodenectomy) for ductal adeno-
carcinoma of the pancreatic head at Seoul National University 
Hospital from 2005 to 2006 were evaluated. No patients received 
any preoperative chemotherapy or radiotherapy. Preoperative 
work-up included laboratory investigations such as tumor mark-
ers (CEA and CA19-9) and radiologic studies (chest radiograph, 
triple phase MDCT in 2.5 mm slice thickness). For further eval-
uation, 3D-GRE MRI with MRCP or 18F-FDG PET/CT were also 
checked. Primary tumor and lymph nodes were prospectively 
collected from all 48 consecutive patients, and resected primary 
tumors and lymph nodes were examined histologically by H&E Lee SE, et al.  •  Lymph Node Micrometastasis in Resectable Pancreatic Cancer
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staining. Histopathologic and TNM classifications were made 
in accordance with the Union Internacional Contra la Cancrum 
(UICC) classification of 2002 (16). Resected lymph nodes in-
cluded; posterior pancreatoduodenal lymph nodes, lymph nodes 
around the celiac axis, common hepatic artery, hepatoduode-
nal ligament, and superior mesenteric artery, and para-aortic 
lymph nodes. A tumor-free margin was achieved in all patients. 
Follow-up durations ranged from 5 to 41.9 months (median, 20 
months) and patient survivals were determined from surgery  
to death or most recent follow-up. All patients were followed-
up after discharge as follows: plain-film radiography every 1-3 
months, and computed tomography every 3-6 months. 
  The study group contained 32 men and 16 women ranging in 
age from 43 to 78 yr (median, 62 yr). One patient had a pT1 tu-
mor and the other 47 patients a pT3 tumor. Pathologically, all 
tumors were invasive ductal adenocarcinomas (46 moderately 
differentiated, 2 poorly differentiated). Of the 48 patients, 17 had 
no lymph node disease (pN0) as determined by H&E staining, 
and the remaining 31 had lymph node involvement (pN1).
Immunohistochemistry
A total of 1,221 lymph nodes (25.4 nodes/patient), including 836 
regional, 160 paraaortic, and 225 paragastric or paracolic nodes, 
were retrieved from the 48 sets of surgical specimens. Among 
the 1,221 lymph nodes, a total of 208 lymph nodes were sam-
pled (4.3 nodes/patient). Two serial 3-μm sections were cut from 
each node area. One section was routinely for H&E stained for 
histologic examination, and the other was stained pan-CK and 
CK-19 mouse monoclonal antibody (DAKO, Glostrup, Denmark) 
for immunohistochemical examination. Antibody binding was 
detected using Vectastain ABC ‘Elite’ avidin/biotin/peroxidase 
kits (Vector laboratories, Burlingame, CA, USA) according to the 
manufacturer’s instructions. After deparaffinizing and rehydrat-
ing sections were pretreated with 10 mM citrate buffer solution 
(pH 6.0) for 15 min in a 700 W or more microwave to retrieve 
antigens, endogenous peroxidase activity was then blocked by 
treating sections with 3% hydrogen peroxide for 6 min. Sections 
were then incubated with primary monoclonal antibody dilut-
ed at 1:100 in PBS at room temperature for 1 hr. After rinsing, 
sections were incubated with secondary antibody, and then 
treated with biotinylated anti-mouse IgG. Reaction products 
were visualized with DAB (diaminobenzidine; Sigma, St. Louis, 
MO, USA) as chromogen, and sections were counterstained with 
Mayer’s hematoxylin. H&E and immunohistochemically stained 
sections were examined independently for metastasis by an ex-
perienced pathologist unaware of clinical details. 
  The term “overt” lymph node metastasis is used to describe a 
metastasis detected during a routine histologic examination by 
H&E staining. The “micrometastasis” is used to describe a me-
tastasis missed by a routine H&E staining but detected by an 
anticytokeratin antibody immunohistochemical study. Lymph 
node micrometastases were visualized as single-cells or as small 
clusters of tumor cells.
Statistics
Results are expressed as mean ± SD. Statistical analysis was per-
formed using Fisher’s exact probability test or the Mann-Whit-
ney U test, as appropriate. Postoperative survivals were calcu-
lated using the Kaplan-Meier method and differences between 
survival curves were compared using the log-rank test. Multi-
variate analysis was conducted using the Cox proportional haz-
ard model. Statistical significance was accepted for P value of < 
0.05.
Ethics statement
This prospective study conformed to the ethical guidelines of 
the Declaration of Helsinki. The institutional review board of 
Seoul National University Hospital approved this study (H-0501-
141-011). Informed consent was obtained from all subjects.
RESULTS 
The study group consisted of 48 patients with ductal adenocar-
cinomas of the pancreas with histologically tumor-free resec-
tion margins (R0). Routine histopathological examinations of 
resected lymph nodes revealed lymph node metastasis in 31 
patients (64.6%) of total 48 patients and 104 (8.5%) of 1,221 re-
sected lymph nodes. 
Detection of nodal micrometastases
For the immunohistochemical analysis, a total of 208 lymph 
nodes from these 48 patients were sampled. Of these sampled 
lymph nodes, H&E staining identified 16 (7.7%) positive nodes 
while immunohistochemical staining identified 24 (11.5%) pos-
itive nodes that were judged to be “tumor-free” by routine his-
topathology including 8 (33.3%) single cell micrometastases and 
16 (66.7%) cluster micrometastases. Of the 17 patients with pN0 
disease, micrometastases were detected in 5 (29.4%) patients 
including two patients with single cell micrometastases and 3 
patients with cluster micrometastases.
  Nodal micrometastases were most frequently found in pos-
terior pancreatoduodenal nodes (28.1%) (Table 1). Clinicopath-
ologic details of the 31 patients with overt metastasis (pN1), of 
Table 1. Distribution of micrometastases 
Location of lymph nodes
Micrometastasis/ 
H&E negative lymph nodes (%)
Lymph nodes around the common hepatic artery 3/37 (8.1) 
Lymph nodes around the celiac trunk 2/25 (8.0)
Lymph nodes of hepatoduodenal ligament   4/39 (10.3)
Posterior pancreatoduodenal lymph nodes   9/32 (28.1)
Lymph nodes around superior mesenteric artery   3/27 (11.1)
Para-aortic lymph nodes 3/32 (9.4)Lee SE, et al.  •  Lymph Node Micrometastasis in Resectable Pancreatic Cancer
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the 5 patients with micrometastasis and without overt metasta-
sis (pN0mi[i+]) and of the 12 patients with neither micrometas-
tasis nor overt metastasis (pN0mi[i-]) are shown in Table 2. Nod-
al micrometastasis was found to be significantly related to tumor 
relapse (P = 0.026).
Impact of nodal micrometastasis on prognosis
The 31 patients with overt node metastasis exhibited significant-
ly worse survival compared with the 17 patients without overt 
node metastasis(median survival; 16.3 vs 27.8 months, P = 0.05). 
Survival of the 21 patients with lymph node micrometastasis 
regardless as to whether the nodal metastasis was overt or not 
was poorer than that of the 27 patients without lymph node mi-
crometastasis (median survival; 12.8 vs 27.3 months, P = 0.008) 
(Fig. 1). The 12 patients without overt metastasis or micrometas-
tasis had a better prognosis than the 5 patients with only nodal 
micrometastasis (median survival; 35.9 vs 8.6 months, P < 0.001) 
(Fig. 2). Five patients with only nodal micrometastasis developed 
tumor relapse within a median time of 3.9 months; relapse oc-
curred in the liver in 4 and in the skull in one.
Prognostic significance of nodal micrometastasis
Univariate analysis revealed that overt lymph node metastasis 
(P = 0.05), lymph node micrometastasis (P < 0.001), poor differ-
entiation (P < 0.001), angiolymphatic invasion (P = 0.05), and an 
elevated preoperative serum CA 19-9 level (P = 0.01) were sig-
nificant poor prognostic factors. Multivariate analysis using the 
Cox proportional hazard model was performed using these five 
significant variables, lymph node micrometastasis (P < 0.001) 
and an elevated preoperative serum CA 19-9 level (P = 0.01) 
were found to be significant independent prognostic factors 
(Table 3). 
DISCUSSION 
Lymph node metastasis is known to be an important prognos-
tic factor in patients with pancreatic cancer. However, even in 
patients with pN0 disease, 5-yr survival rates following resec-
tion have been reported to be as low as 5%-36% (17-19). The 
question why some node negative patients die within a few 
Table 2. Clinicopathologic features of the patients with pN1 (overt nodal metastasis), 
pN0mi(i+) (no overt nodal metastasis and micrometastasis) and pN0mi(i-) (neither 
overt nodal metastasis nor micrometastasis)
Parameters
 pN1  
 (n = 31)
pN0 (n = 17)
P value   mi(i+)  
  (n = 5)        
  mi(i-)  
  (n = 12)
Age (mean, years) 61.5 ± 9.6 64.6 ± 5.1 63.0 ± 7.6 0.722
Male/Female 22:9 3:2 7:5 0.726
Elevated preop. CEA   6 (21.4%) 0    4 (33.3%) 0.129
Elevated preop. CA19-9 24 (77.4%) 5 (100%)    5 (41.7%) 0.015
Size (cm)   3.2 ± 1.0   3.0 ± 2.2   2.8 ± 0.9 0.585
T stage (T1/2/3) 0/1/30 0/0/5 1/0/11 0.222
Cellular differentiation
   Moderate
   Poor
 
29 (93.5%)
2 (6.5%)
 
5
0
 
12
  0
0.564
 
 
Angiolymphatic  invasion 20 (71.4%)  1 (20.0%)    5 (41.7%) 0.042
Perineural invasion 26 (89.7%)  4 (80.0%)    9 (75.0%) 0.519
Venous invasion   6 (21.4%)  1 (20.0%) 1 (8.35) 0.148
Recurrence
   Local
   Systemic
26 (83.9%)
  3 (12.0%)
23 (88.0%)
5 (100%)
0
5 (100%)
   6 (50.0%)
   2 (28.6%)
   4 (71.4%)
0.026
Disease free survival (mo) 11.3 ± 8.2   3.4 ± 1.6 17.2 ± 9.2 0.008
Overall survival (mo) 19.7 ± 9.7   7.6 ± 2.1   25.5 ± 13.0 0.008
Fig. 1. Overall survival graph. Outcome after resection for patients without nodal mi-
crometastasis compared favorably with those with nodal micrometastasis (P = 0.008). 
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Fig. 2. Overall survival graph. The outcome after resection in patients with neither 
overt nodal metastasis nor nodal micrometastasis compared favorably with those 
with no overt nodal metastasis and nodal micrometastasis (P < 0.001). 
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Table 3. Results of multivariate Cox regression analysis for prognostic factors
Factors B   Exp (B)   P value 95% CI
Elevated preop. CA 19-9 1.410   4.0940       0.006   1.487-11.277
Lymph node  
   micrometastasis
4.189 0.015 < 0.01 0.002-0.124Lee SE, et al.  •  Lymph Node Micrometastasis in Resectable Pancreatic Cancer
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months after curative resection is not sufficiently answered be-
cause of metastases or local recurrence whereas others enjoy a 
more favorable outcome. Early metastatic relapse after complete 
resection of an apparently localized primary pancreatic cancer 
lesion indicates that disseminated tumor cells, undetectable by 
current methods, were probably present at the time of surgery. 
Knowledge about occult metastases is essential to patients and 
their physicians in deciding on a course of adjuvant treatment 
to improve the postoperative outcome. 
   In this study, we detected the lymph node micrometastasis 
by the immunohistochemical staining for cytokeratin. Although 
conclusive results are not available, cytokeratin is a component 
of the cytoskeleton of epithelial cells that is not present in nor-
mal lymph nodes; therefore, immunohistochemistry using an 
antibody that recognizes cytokeratin enables the detection of 
minute deposits of tumor cells in the lymph nodes. We hypoth-
esized that the relatively low survival rate of node-negative pan-
creatic cancer could result from the presence of lymph node mi-
crometastasis. Only patients without a gross residual tumor were 
used in this study because it might have concealed the prognos-
tic significance of nodal micrometastasis and the present study 
shows that isolated tumor cells or small tumor cell clusters de-
tected in lymph nodes using a sensitive immunohistochemical 
assay method independently predict relapse-free and overall 
survival in pancreatic cancer, regardless of overt nodal status. 
  Comparing with other studies (1, 14, 15) on pancreas cancer 
and other carcinomas (2, 4-11, 20-22), our study appeared a con-
tradictory result that five of our patients with nodal microme-
tastasis but no overt metastasis achieved poorer survival than 12 
patients without neither micrometastasis nor overt metastasis 
(Fig. 2). This number is far too small to allow a firm conclusion 
to be drawn, but considering the previous study (23) about gall-
bladder cancer that reported similar results, we could explain 
the results as follows. Nodal micrometastasis presents as single 
cells or small clusters of tumor cells. It is likely that single cells or 
small clusters of cells can migrate more easily within the lym-
phatic system than larger cell aggregates. These free cancer cells 
in the lymphatic system could enter the systemic blood stream 
by a venous route or via the thoracic duct, and then spread sys-
temically. We therefore think that nodal micromeatstasis could 
be also an indicator of systemic spread. In our series, tumor re-
lapse occurred predominantly at distant sites in patients with 
nodal micrometastasis. This finding suggests that these cells are 
indicators of generalized occult metastatic disease with a high 
load of residual tumor cells, rather than indicators of advanced 
locoregional disease that might be controlled by radical tumor 
resection with tumor free resection margins. However, till now, 
it is unclear the potential of disseminated cells to develop into 
overt metastasis. 
  Some defined micrometastasis as metastatic tumor cells not 
detectable on routine histologic examination, whereas others 
(24-27) considered metastatic tumor cells by size into “micro-
metastases” (measuring > 0.2 mm) and “isolated tumor cells” 
(measuring ≤ 0.2 mm), as recommended by the sixth edition of 
the TNM classification of malignant tumors by UICC (16). Our 
definition of micrometastasis was the presence of tumor cells in 
regional lymph nodes not detected on routine H&E staining and 
we divided the metastasis into single-cell and cluster types in 
light of previous suggestions that this differentiation may be im-
portant (24-27). However, in our study, the patient number ana-
lyzed (single cell micrometastases, n = 2, cluster micrometastases, 
n = 3) was too small to compare the prognosis between two groups. 
Further discussions are required to reveal the difference in prog-
nostic impact between single and cluster micrometastases.   
  In the present study, only 2 serial sections from each lymph 
node, 1 for routine H&E staining and another for immunohis-
tochemical staining, were examined for metastasis. Although 
the examination of a representative section per node is standard 
practice at our institution and others (9, 11, 28), some authors 
recommended the use of multiple sections (20-22). If we had 
used multiple sections, the incidences of nodal micometastasis 
might have been higher. However, because immunohistochem-
ical examinations for lymph node micrometastasis are time-con-
suming and rather expensive, there is still no consensus about 
how many slides should be considered as representative sam-
ples for the detection of micro-metastases.
  In conclusion, our study suggests that lymph node microme-
tastasis is the predictor of reduced survival and indicate aggres-
sive tumor biology among patients undergoing curative resec-
tion for pancreas cancer. Although our study was prospective in 
nature and, hence, free from biases that may arise from retro-
spective reviews, it is limited by small sample size to reach a def-
inite conclusion. Elucidation of the characteristics of the dissem-
inated cancer cells are required for future researches and it is 
likely that in the future a prognostic profile combining primary 
tumor characteristics and nodal analysis will be part of a more 
comprehensive staging schema similar to that currently being 
used in breast cancer. 
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